Pompe disease is a rare multisystemic disease with prominent muscle symptoms caused by the defi ciency of acid alpha-glucosidase, which is involved in glycogen degradation. The clinical spectrum ranges from the severe and rapidly progressive infantile form (IOPD) with hypotonia, prominent cardiac and respiratory involvement, to late-onset forms (LOPD) characterised by milder and more heterogeneous phenotypes where the progressive muscle involvement is prominent. Enzyme replacement therapy (ERT), with recombinant human alglucosidase alpha, became available in 2006; in recent years, an increasing number of studies in treated patients have been published, focusing on effi cacy, immune tolerance, possible biomarkers and appropriate outcome measures.
modulation strategies in CRIM-negative patients could improve treatment effi cacy.
As regards LOPD, ERT has a moderate effect compared to IOPD results. In 2012, a systematic literature review identifi ed 21 studies with ERT effi cacy/safety results and showed that at least two-thirds of patients had improved muscular and/or respiratory function. Other studies have later provided evidence that treatment responses seem to be more prominent during the fi rst 2 years of treatment than thereafter, although in some of the largest cohorts studied, the therapeutic effect was maintained up to 36 months. Other authors outlined the characteristics of LOPD responders and they identifi ed as favourable prognostic factors female gender, younger age, better clinical status and early ERT start. Nevertheless, the majority of studies lack long-term ERT results: very few of them report on patients treated over 36 months.
In conclusion, we likely need to reconsider guidelines to start therapy, maybe taking into consideration not only the clinical assessment but even relevant laboratory data (i.e. MRI, enzyme activity, morphological fi ndings) that may help identify early when to start therapy.
In the meantime, new drugs are under development and have shown promising results, suggesting new therapeutic opportunities to improve the quality of life of patients. 
